• Corpus ID: 31530618

Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China.

  title={Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China.},
  author={Le Zhang and Ling-yun Wang and Yan-ming Deng and Fenghua Wang and Fen Feng and Yong-chang Chen and Xin An and Cui Chen and Rui-hua Xu and Yu-hong Li},
  journal={Journal of B.U.ON. : official journal of the Balkan Union of Oncology},
  volume={16 4},
PURPOSE Small bowel adenocarcinoma (SBA) is a rare malignancy, and most patients present with unresectable or metastatic disease. Thus far, no standard chemotherapeutic regimen has been established and related data are scarce, especially in Eastern countries. The purpose of this multicenter study was to evaluate the efficacy and toxicity of oxaliplatin combined with fluoropyrimidines in Chinese patients with advanced SBA. METHODS Advanced SBA patients who received FOLFOX (5-fluorouracil/5-FU… 
ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma
In the largest study of SBA to date, pembrolizumab did not induce the hypothesized response rate; however, it did identify responses in key biomarker-selected cohorts.
Palliative chemotherapy for patients with synchronous metastases of small-bowel adenocarcinoma: A reflection of daily practice
In patients with metastatic SBA, a minority of patients were treated with palliative chemotherapy, and first-line treatment consisted predominantly of oxaliplatin-based combination chemotherapy, whereas second- line treatment was mainly irinotecan-based.
Clinical use of molecular targeted agents for primary small bowel adenocarcinoma: A multicenter retrospective cohort study by the Osaka Gut Forum.
The results of the present study indicate that chemotherapy containing molecular targeted agents is a well-tolerated and effective treatment option for SBA.
Clinicopathological features and treatment outcomes of metastatic or locally unresectable small bowel adenocarcinoma.
The prognosis of metastatic or locally unresectable SBA was poor, and unresectedPrimary tumor and males were significantly associated with poor OS, and combined modality therapy of systemic chemotherapy combined with local treatment of the primary tumor and oligometastasis might improve prognosis in selected patients.
Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study
Considering the limited number of patients receiving first-line bevacizumab and the unknown reasons to prescribe additional targeted therapy, the corresponding survival rates of patients treated with and without additional bevacsuzumab in first- line treatment might suggest a limited clinical effect of bevacanalyst in addition tofirst-line palliative chemotherapy on OS.
Treatment of peritoneal metastases from small bowel adenocarcinoma
Based on available evidence, fluoropyrimidine–oxaliplatin should be regarded as optimal first line systemic treatment for PM from SBA and appears safe and may be more effective than systemic therapy as single treatment.
Prognostic factors and treatment outcomes in patients with non-ampullary small bowel adenocarcinoma
Precaution of the disease in early phase, radical resection of the primary tumor while resectable, followed with in-time chemotherapy might improve prognosis and survival of patients with SBA.
Small bowel adenocarcinoma - terra incognita: A demand for cross-national pooling of data
Since no consensus exists on the adequate treatment of these malignancies, it is demanded an international collaboration and cross-national data pooling to pave the way for the implementation of evidence-based standard care operating procedures.
Management of Advanced Small Bowel Cancer
Immunotherapy for small bowel adenocarcinomas, several multikinase inhibitors in resistant GIST patients, as well as everolimus and 177Lu-DOTATATE in neuroendocrine tumors are only few of the novel therapeutic options that have changed, or may change, the therapeutic landscape of these rare cancers.